Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tacrolimus
Therapeutic Area : Urology
Study Phase : Phase II
Sponsor : Lipella Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite
Details : The collaboration aims to facilitate Chemistry, Manufacturing, and Control documentation for Lipella's drug candidate LP-10 (liposomal tacrolimus), aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
April 17, 2023
Lead Product(s) : Tacrolimus
Therapeutic Area : Urology
Highest Development Status : Phase II
Sponsor : Lipella Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Iltamiocel
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
March 20, 2023
Lead Product(s) : Iltamiocel
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Muscle Derived Cell
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access Program for Autologous Muscle Derived Cells (AMDCs)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
December 10, 2020
Lead Product(s) : Autologous Muscle Derived Cell
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 25, 2019
Details : Undisclosed
Product Name : AMDC-USR
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
April 07, 2017
Lead Product(s) : Autologous Muscle Derived Stem Cell
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase I
Recipient : Peter Belafsky, MD
Deal Size : Inapplicable
Deal Type : Inapplicable
Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR) for Tongue Dysphagia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 20, 2016
Lead Product(s) : Autologous Muscle Derived Stem Cell
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I
Recipient : Peter Belafsky, MD
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Autologous Muscle-Derived Cell
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 14, 2014
Lead Product(s) : Autologous Muscle-Derived Cell
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Autologous Muscle Derived Cells for Female Urinary Sphincter Repair
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
July 08, 2013
Lead Product(s) : Iltamiocel
Therapeutic Area : Gastroenterology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Autologous Cell Therapy for Treatment of Fecal Incontinence
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
May 17, 2012
Lead Product(s) : Iltamiocel
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 27, 2011